Reports Q2 revenue $217.2M, consensus $204.01M. Adjusted EBITDA less noncontrolling interests was $31.5 million as compared to $27.4 million in Q2 2017; Total dialysis treatments increased 5.6%, of which 4.5% was non-acquired growth. Normalized total treatment growth was 6.3% and normalized non-acquired growth was 5.3%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.